Hypera S.A.

HYPE3.SA

SAO

25.35

BRL

-2.22(-8.05%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Hypera S.A. fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

19.5

Price/Book

1.31

Debt/Equity

76.14%

Return on Equity

6.85%

Dividend Yield

4.61%

EBITDA

2.23B

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	4,088,871,000	5,937,373,000	7,546,355,000	7,914,658,000	7,442,466,000
Gross Profit	2,629,275,000	3,802,886,000	4,761,524,000	4,995,544,000	4,380,999,000
Operating Income	1,285,376,000	2,036,292,000	2,459,340,000	2,497,918,000	1,795,769,000
Net Income	1,295,116,000	1,330,208,000	1,696,697,000	1,647,960,000	1,340,990,000
Total Assets	17,249,810,000	19,817,962,000	23,755,633,000	24,508,751,000	24,559,083,000
Total Current Liabilities	2,623,249,000	2,776,526,000	5,225,194,000	4,644,236,000	3,940,088,000
Total Equity	9,240,715,000	9,833,471,000	10,655,441,000	11,517,873,000	12,101,819,000
Free Cash Flow	-744,161,000	560,249,000	529,337,000	1,583,280,000	1,767,332,000
Cash from Operations	1,183,054,000	1,399,131,000	2,038,793,000	2,395,993,000	2,539,599,000
Cash from Investing	-1,895,113,000	-4,412,425,000	-1,742,337,000	-791,188,000	-592,438,000
Cash from Financing	3,208,921,000	557,058,000	278,955,000	-1,886,385,000	-2,788,727,000
Net Change in Cash	2,496,862,000	-2,456,236,000	575,411,000	-281,580,000	-841,566,000